Albendazole induces immunotherapy response by facilitating ubiquitin-mediated PD-L1 degradation

BACKGROUND: Immune checkpoint inhibitors (ICIs) have been increasingly used in patients with various cancers and have shown efficient therapeutic outcomes. However, fewer than 40% of cases across multiple cancer types show a response to ICIs. Therefore, developing more efficient combinational approa...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Lin, Kuang, Xinwei, Zhang, Guanxiong, Liang, Long, Liu, Dandan, Hu, Bin, Xie, Zuozhong, Li, Hui, Liu, Hong, Ye, Mao, Chen, Xiang, Liu, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115032/
https://www.ncbi.nlm.nih.gov/pubmed/35577504
http://dx.doi.org/10.1136/jitc-2021-003819

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115032/
https://www.ncbi.nlm.nih.gov/pubmed/35577504
http://dx.doi.org/10.1136/jitc-2021-003819

Ejemplares similares